Clinical Trial Update: Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 dose-ranging study evaluating topical rapamycin cream for facial angiofibroma in tuberous sclerosis complex has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facial Angiofibroma
• Tuberous Sclerosis

Drugs mentioned

• topical rapamycin cream (rapamycin)

Snippet

Sponsor: Dermatology Specialties Limited Partnership | Conditions: Facial Angiofibroma, Tuberous Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-08-14